Lingdolinurad - Atom Bioscience
Alternative Names: ABP-671Latest Information Update: 09 Dec 2024
At a glance
- Originator Atom Bioscience
- Class Antigouts; Antirheumatics; Small molecules; Uricosurics
- Mechanism of Action SLC22A12 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Gout
- Phase II Hyperuricaemia
Most Recent Events
- 03 Dec 2024 Atom Therapeutics and China Medical System Holdings enter into an exclusive commercialization agreement for Lingdolinurad in China, Hongkong and Macau
- 05 Sep 2024 Atom Bioscience terminates a Phase-II/III extension clinical trials in Gout in Taiwan, Georgia, Guatemala, Australia and USA(PO) due to redesign of clinical development program for ABP-671 (NCT06276556)
- 24 Apr 2024 Atom Bioscience initiates enrollment in phase II/III trial in Gout in USA (PO) (NCT05818085)